SCHEMBL4919930

SCHEMBL4919930

c1cncc(-c2cc(C3CC[N]3)on2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP2E1 P05181 1/20 0.50
CYP2B6 P20813 1/20 0.50
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
CHRNB2 P17787 1/20 0.42
CHRNA5 P30532 1/20 0.42
CHRNA4 P43681 1/20 0.42
USP30 Q70CQ3 1/20 0.41
PPARA Q07869 3/20 0.41
TP53 P04637 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
CYP19A1 P11511 2/20 0.40
ALDH1A1 P00352 3/20 0.39
CYP1A2 P05177 3/20 0.39
CYP3A4 P08684 3/20 0.39
PKM P14618 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3853565 0.91 CYP2C9 (0.47) CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6
SCHEMBL29897243 0.88 RAB9A (0.55) CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6
SCHEMBL11835580 0.88 RAB9A (0.55) CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6
SCHEMBL4919068 0.77 NISCH (0.35) NPC1RAB9AALDH1A1PKMKDM4E
SCHEMBL14466245 0.76 CYP2C9 (0.46) CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6
SCHEMBL14466141 0.76 CYP2C9 (0.46) CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6
SCHEMBL4036212 0.76 CHRNB2 (0.54) CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6
SCHEMBL4919484 0.74 NPC1 (0.36) NPC1RAB9ATP53SMN1; SMN2ALDH1A1
SCHEMBL4401708 0.74 KDM4E (0.42) NPC1RAB9AUSP30TP53SMN1; SMN2
SCHEMBL2309158 0.73 CYP2A6 (0.59) CYP2A6CYP2C9CYP2C19CYP2E1CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161278-A1 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity ASTRAZENECA AB (SE) 2008-07-03 US disclosed
EP-1863797-A1 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY AstraZeneca AB (SE) 2007-12-12 EP disclosed
WO-2006100461-A1 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY ASTRAZENECA AB (SE) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161278-A1 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity IGF1R, IGFBP1, IGFBP2 CYP2A6 3860/4885CYP2C9 3863/4885CYP2C19 2230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.